-

Builders FirstSource Raises More Than $1 Million for The Leukemia & Lymphoma Society at Annual Charity Event

IRVING, Texas--(BUSINESS WIRE)--Builders FirstSource proudly announces that its recent Annual Charity Event for The Leukemia & Lymphoma Society (LLS) successfully raised over $1 million for LLS, demonstrating the company's enduring commitment to fighting blood cancers. The event took place in Las Colinas, TX on May 9 and 10.

Since initiating its partnership with LLS in 2006, Builders FirstSource has helped raise more than $11 million towards critical research, patient support, and advocacy programs dedicated to advancing treatments and cures for blood cancers.

"We are deeply appreciative of the overwhelming support from our partners, which enabled us to make this significant contribution to The Leukemia & Lymphoma Society,” said Dave Rush, President and CEO of Builders FirstSource. “Every dollar raised represents our commitment to supporting those affected by blood cancers. Together, we are building hope and advancing the cause to find cures."

The event featured Hall of Fame Basketball Coach Roy Williams as a keynote speaker, who discussed the profound impact cancer has had on his family and friends. He went on to draw parallels between teamwork in sports and life, emphasizing the importance of collaboration and leadership. "It’s amazing how much can be achieved when no one cares who gets the credit," Williams noted.

“We are profoundly grateful to everyone who has celebrated, honored, and remembered those impacted by blood cancer," expressed Coker Powell, LLS SVP and Chief Development Officer. "Through the unwavering support and generosity of Builders FirstSource and its partners, we are empowered to advance towards a world without blood cancer. Their steadfast support directly fuels LLS's mission: pioneering cutting-edge treatments, providing vital resources to patients and families navigating their blood cancer journeys, and championing accessible and affordable healthcare for all.”

The 2024 event attracted sponsorship from notable companies including: Accenture, Alpine ITW, American Gypsum, Andersen Windows & Doors, The AZEK Company, Boise Cascade, Canfor, Capital Lumber, Century Communities, Cisco, Commvault, Cornerstone Building Brands, Composite Technology International, DAP Global Inc., Doman Building Materials Group, D.R. Horton, DuPont, EVOTEK, Georgia-Pacific, Great Southern Wood Preserving, Hampton Lumber, James Hardie, JELD-WEN, Knauf Insulation, LP Building Solutions, The Marwin Company, Meritage Homes, Metrie, M/I Homes, MiTek, MITER Brands, Novo Building Products, ODL, Okta, OrePac Building Products, Owens Corning, Ox Engineered Products, Pacific Woodtech, Pella Windows and Doors, Perficient, Plastpro, PrimeSource Building Products, Reeb, Simpson Strong-Tie, Specialty Building Products, Steves & Sons, Therma-Tru Doors, Trellix, Trex, Versatex Building Products, Weyerhaeuser, and Woodgrain.

Looking forward, Builders FirstSource aims to raise at least $2 million for LLS in 2024. The company will continue its engagement through various fundraising initiatives, including LLS’s Light The Night® walks, where blood cancer survivors and supporters gather to raise funds for research, advocacy, and patient services.

For more information on Builders FirstSource’s charity initiatives, please visit here.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the global leader in the fight against blood cancer. LLS is united in its mission to cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has regions throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

For additional information visit lls.org/lls-newsnetwork. Follow us on Facebook, Instagram, and LinkedIn.

Contacts

Heather Kos
SVP, Investor Relations
Builders FirstSource, Inc.
investorrelations@bldr.com

Builders FirstSource, Inc.


Release Versions

Contacts

Heather Kos
SVP, Investor Relations
Builders FirstSource, Inc.
investorrelations@bldr.com

More News From Builders FirstSource, Inc.

Builders FirstSource Reports Third Quarter 2025 Results

IRVING, Texas--(BUSINESS WIRE)--Builders FirstSource, Inc. (NYSE: BLDR) today reported its results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights All Year-Over-Year Comparisons Unless Otherwise Noted: Net sales were $3.9 billion, a 6.9% decrease, driven by lower core organic net sales and commodity deflation, partially offset by growth from acquisitions. Gross profit margin decreased 240 basis points to 30.4%, primarily driven by a below-normal starts environment....

Builders FirstSource to Host Third Quarter 2025 Financial Results Conference Call and Webcast

IRVING, Texas--(BUSINESS WIRE)--Builders FirstSource, Inc. (NYSE: BLDR) (“Builders FirstSource” or the "Company") will host a conference call and webcast on Thursday, October 30, 2025, to discuss the Company’s financial results and other business matters. The teleconference will begin at 8:00 a.m. Central Time and will be hosted by Peter Jackson, President and Chief Executive Officer, and Pete Beckmann, Chief Financial Officer. The live webcast can be accessed on the Company's investor relation...

Builders FirstSource Charity Event Raises $1.6 Million for Blood Cancer United

IRVING, Texas--(BUSINESS WIRE)--Builders FirstSource (NYSE: BLDR) today announced that its 2025 charity event held Sept. 24-25 raised approximately $1.6 million for Blood Cancer United (formerly known as The Leukemia & Lymphoma Society). This marks the 19th year of the Builders FirstSource partnership with Blood Cancer United, which has helped raise a total of more than $15 million for critical research, patient support, and advocacy programs dedicated to advancing treatments and cures for...
Back to Newsroom